GlobeNewsWire
14 Sept 2026, 06:00 UTC · 2h ago
Verdict
Headline takes no side. We score NANO +0.80 across four claims.
Our read: bullish.
NANO score
+0.80
More positive than 88% of ticker scores this week
Price reaction
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by
What the story claims
4 claims · scored −1 bearish … +1 bullish
JNJ-1900 (NBTXR3) demonstrated a one-year locoregional control rate of 79% and a one-year local progression-free survival rate of 61% in inoperable recurrent NSCLC patients.
So whatPositive efficacy data in a high-unmet-need oncology setting typically drives significant valuation increases for biotech firms.
More positive than 92% of claims this week
The Phase 1 study reported no dose-limiting toxicities or Grade 3 or higher adverse events specifically related to JNJ-1900 or the injection procedure.
Continue reading
5 related stories
Top 1 mover · tap to explore
More positive than 77% of claims this week
Investigators established a recommended Phase 2 dose at 33% of gross tumor volume based on the completed cohort results.
More positive than 66% of claims this week
Nanobiotix plans to enroll additional patients in this study following the encouraging findings.
More positive than 55% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company announced positive Phase 1 results showing clinically meaningful local control and no dose-limiting toxicities for JNJ-1900.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
9h ago
Price reaction
No price data for NANO right now.
